Trial reportThe American journal of cardiology2018
Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.
Trial report in The American journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286423 (Colchicine in Acutely Decompensated Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colchicine in Acutely Decompensated Heart Failure With Reduced Ejection Fraction: a Pilot Study
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Effects of calcium supplementation on changes in the IL2, IL4, IL6, IL10 axes and oxidative stress in pregnant women at risk for pre-eclampsia.BMC pregnancy and childbirth · 2024Trial
- Comparison of Safety and Biological Efficacy of Anakinra (Kineret) Dispensed in Polycarbonate Plastic versus Borosilicate Glass Syringes: A Patient-Level Analysis of VCUART2 and VCUART3 Clinical Trials.The Journal of pharmacology and experimental therapeutics · 2023Trial
- Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure.The American journal of cardiology · 2022Trial
- Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.Journal of the American Heart Association · 2020Trial
- Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure.International journal of molecular sciences · 2020Trial
- An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Tribulations of Randomized Controlled Trials: Testing the Inflammatory Hypothesis of Heart Failure.Circulation. Heart failure · 2026Article
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Multiorgan characterization of inflammasome component expression in a rat model of advanced heart failure.ESC heart failure · 2025Article
- Systemic inflammation-based Glasgow Prognostic Score as a prognostic indicator in chronic heart failure.International journal of cardiology. Heart & vasculature · 2025Article
- Mechanisms of mitochondrial damage-associated molecular patterns associated with inflammatory response in cardiovascular diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Characterization of ferroptosis-triggered pyroptotic signaling in heart failure.Signal transduction and targeted therapy · 2024Article
- IL-1 signaling pathway, an important target for inflammation surrounding in myocardial infarction.Inflammopharmacology · 2024Review
- The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.Nature reviews. Cardiology · 2024Review
- Xin-Li formula attenuates heart failure induced by a combination of hyperlipidemia and myocardial infarction in rats via Treg immunomodulation and NLRP3 inflammasome inhibition.Journal of traditional and complementary medicine · 2023Article
- Association of perivascular fat attenuation on computed tomography and heart failure with preserved ejection fraction.ESC heart failure · 2023Article
- P2X3 receptor antagonism attenuates the progression of heart failure.Nature communications · 2023Article
- Experimental heart failure models in small animals.Heart failure reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Interleukin-1β (IL-1β) is a cytokine involved in atherothrombosis and is known to depress cardiac function. We hypothesized that blocking IL-1β in patients with symptomatic systolic heart failure (HF) would improve their cardiorespiratory fitness. The purpose of the study was to measure changes in peak oxygen consumption (VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.